Cognitive Dysfunction (CD) can occur in Systemic Lupus Erythematosus (SLE) before the occurrence of Neuropsychiatric Lupus Erythematosus (NPSLE). Given the reversibility and fluctuation of SLE-related CD, the research for possible predictors is of great significance for early detection and intervention.
Objective
We sought to determine the prevalence, involved domains, and possible predictors of CD in SLE patients.
Methods
We conducted a retrospective cross-sectional study at Nanfang Hospital from 2018 to 2019. A total of 78 SLE patients were recruited. The Montreal Cognitive Assessment (MoCA) scale was used to screen cognitive function. Demographic, clinical, and laboratory characteristics were collected. The serum anti-methyl-d-aspartate receptor (anti-NMDAR) antibody and S100β were measured by enzyme-linked immunosorbent assay (ELISA). Multivariate logistic regression analysis and ROC curve were used to assess the predictor of SLE-related CD.
Results
Of 78 recruited patients,53 (67.9%) had CD. It mainly involved delayed recall, abstract generalization, verbal repetition, and fluency. The disease activity index (SLEDAI) was not associated with SLE-related CD (p > 0.05). Multivariate logistic regression showed that an increase in each year of education there was a decrease in the likelihood of CD (OR 0.261, CI 0.080-0.857, p = 0.027) whereas with each unit increase in serum anti-NMDAR antibody there was an increased likelihood of SLE-related CD (OR 1.568, CI 1.073–2.292, p = 0.020).
Conclusion
The prevalence of SLE-related CD was 67.9% in our study and SLE-related CD was not associated with disease activity. Serum anti-NMDAR antibody can be used as a predictor for SLE-related CD.
The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999;
42: 599–608.
2.
AhnGYKimDWonS, et al.
Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus2018;
27: 1338–1347.
3.
ZabalaASalgueiroMSáez-AtxukarroOBallesterosJRuiz-IrastorzaGSegarraR.Cognitive impairment in patients with neuropsychiatric and non-neuropsychiatric systemic lupus erythematosus: a systematic review and Meta-analysis. J Int Neuropsychol Soc2018;
24: 629–639.
4.
TaySHFairhurstAMMakA.Clinical utility of circulating anti-N-methyl-d-aspartate receptor subunits NR2A/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus and Sjögren's syndrome: an updated Meta-analysis. Autoimmun Rev2017;
16: 114–122.
5.
LapaATPostalMSinicatoNA, et al.
S100β is associated with cognitive impairment in childhood-onset systemic lupus erythematosus patients. Lupus2017;
26: 478–483.
6.
TaySHMakA.Anti-NR2A/B antibodies and other major molecular mechanisms in the pathogenesis of cognitive dysfunction in systemic lupus erythematosus. Int J Mol Sci2015;
16: 10281–10300.
7.
HochbergMC.Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
RayesHATaniCKwanA, et al.
What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum2018;
48: 240–255.
10.
DunstanDAScottNToddAK.Screening for anxiety and depression: reassessing the utility of the zung scales. BMC Psychiatry2017;
17: 329.
11.
Paez-VenegasNJordan-EstradaBChavarria-AvilaE, et al.
The Montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. J Clin Rheumatol2018;
25: 1–328.
12.
HuangLChenKLLinBY, et al.
Chinese version of Montreal cognitive assessment basic for discrimination among different severities of Alzheimer's disease. Neuropsychiatr Dis Treat2018;
14: 2133–2140.
13.
DunstanDAScottN.Clarification of the cut-off score for Zung’s self-rating depression scale. BMC Psychiatry2019;
19: 177.
14.
HoRCThiaghuCOngH, et al.
A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev2016;
15: 124–138.
15.
KelloNAndersonEDiamondB.Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials. Arthritis Rheumatol2019;
71: 1413–1425.
16.
ArinumaY.Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol2018;
31: 294–299.
17.
GonzálezAMassardoL.Antibodies and the brain: antiribosomal P protein antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol2018;
31: 300–305.
18.
WangYTangJShenL, et al.
Effects of dexamethasone on MRL/LPR mice with systemic lupus erythematosus complicated with cognitive dysfunction. Zhong Nan Da Xue Xue Bao Yi Xue Ban2017;
42: 251–256.
19.
ShucardJLGainesJJAmbrusJJrShucardDW.C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn Behav Neurol2007;
20: 31–37.
20.
TomiettoPAnneseVD'agostiniS, et al.
General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum2007;
57: 1461–1472.
21.
KanapathyANik JaafarNRShaharirSSChanLFRozitaMCh'ngSS.Prevalence of cognitive impairment using the Montreal cognitive assessment questionnaire among patients with systemic lupus erythematosus: a cross-sectional study at two tertiary centres in Malaysia. Lupus2019;
28: 854–861.
22.
AdhikariTPiattiALuggenM.Cognitive dysfunction in SLE: development of a screening tool. Lupus2011;
20: 1142–1146.
23.
LillisTATironeVGandhiN, et al.
Sleep disturbance and depression symptoms mediate the relationship between pain and cognitive dysfunction in lupus patients. Arthritis Care Res)2019;
71: 406–412.
24.
MonasteroRBettiniPDel ZottoE, et al.
Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci2001;
184: 33–39.
OmdalRBrokstadKWaterlooKKoldingsnesWJonssonRMellgrenSI.Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol2005;
12: 392–398.
27.
MenonSJameson-ShortallENewmanSPHall-CraggsMRChinnRIsenbergDA.A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum1999;
42: 735–741.
28.
OwensTWekerleHAntelJ.Genetic models for CNS inflammation. Nat Med2001;
7: 161–166.
29.
PortelaLVBrenolJCWalzR, et al.
Serum S100b levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol2002;
9: 164–166.
30.
KuoHKYenCJChangCHKuoCKChenJHSorondF.Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and Meta-analysis. Lancet Neurol2005;
4: 371–380.
31.
DormanGMicelliMCosentinoV, et al.
Cognitive dysfunction in systemic lupus erythematosus in relation to disease activity and damage. Medicina (B Aires)2017;
77: 257–260.
32.
KatzPJulianLTonnerMC, et al.
Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res2012;
64: 502–510.
33.
WaterlooKOmdalRHusbyGMellgrenSI.Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology (Oxford)2002;
41: 411–415.
34.
FujitaYFukuiSIshidaM, et al.
Reversible cognitive dysfunction in elderly-onset systemic lupus erythematosus successfully treated with aggressive immunosuppressive therapy. Intern Med2018;
57: 3025–3028.
35.
McLaurinEYHollidaySLWilliamsP, et al.
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology2005;
64: 297–303.
36.
TarrTPappGNagyNCserépEZeherM.Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol2017;
36: 327–333.
37.
SaidFABetoniTBMagalhaesVNisiharaRSkareTL.Rheumatoid arthritis and cognition dysfunction: lack of association with cumulative glucocorticoid use. Immunopharmacol Immunotoxicol2019;
41: 565–567.
